CTIC 第二贴。

葉芬

20/11/09

Cell Therapeutics, Inc. (CTIC) - Alert Alert! CTIC is actually showing signs of life! The stock continues to trend higher this weak and despite a horrible stock market Thursday, CTIC broke to a new weekly high at $1.14. Resistance is located at $1.14 which is the 50 day moving average as well as $1.21. A break above $1.21 would be huge and would cause me to jump back into the stock for a trade.

葉芬

好消息？ ？看股價會上多少。。。


Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group --CTI to seek recovery from

Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group --CTI to seek
recovery from The Lash Group for damages including reimbursement of prior expenses from the 2007 settlement
with United States government concerning TRISENOX

Fri Nov 20 03:30:00 2009
EST
SEATTLE, Nov 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the
Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that
CTI should be allowed to pursue all of its claims against The Lash Group, sending
the case back to the District Court for trial.  CTI filed a complaint against The
Lash Group, CTI's former third-party reimbursement consultant for CTI's product
TRISENOX, in 2007 seeking $22.8 million in damages for expenses already incurred
related to the investigation, defense and a settlement of claims by the U.S. government
concerning Medicare reimbursement for TRISENOX and other business losses.
In 2007, CTI settled the claims by the U.S. government without admitting
liability and filed a lawsuit including claims that The Lash Group had breached
its contractual obligations to CTI as related to its services, as well as an obligation
to indemnify the company for damages related to the settlement. CTI sold TRISENOX
in 2005 to Cephalon, Inc.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at making cancer more
treatable. For additional information, please visit www.CellTherapeutics.com.
Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert
This press release includes forward-looking statements that involve a number
of risks and uncertainties, the outcome of which could materially and/or adversely
affect actual future results and the trading price of the securities of CTI. Specifically,
the risks and uncertainties include risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and the possibility that
CTI may not be successful in obtaining a judgment for damages and that The Lash
Group may appeal any award given, CTI's ability to continue to raise capital as
needed to fund its operations, competitive factors, technological developments,
costs of developing, producing and selling pixantrone, and the risk factors listed
or described from time to time in CTI's filings with the Securities and Exchange
Commission including, without limitation, CTI's most recent filings on Forms 10-K,
10-Q and 8-K. Except as may be required by law, CTI does not intend to update or
alter its forward-looking statements whether as a result of new information, future
events, or otherwise.



Media Contact:                      Investors Contact:

Dan Eramian                         Ed Bell
T: 206.272.4343                     T: 206.272.4345
C: 206.854.1200                     Lindsey Jesch Logan
F: 206.272.4434                     T: 206.272.4347
E: deramian@ctiseattle.com          F: 206.272.4434
www.celltherapeutics.com/press_room E: invest@ctiseattle.com
                                    www.celltherapeutics.com/investors



SOURCE  Cell Therapeutics, Inc.http://www.celltherapeutics.com
Copyright (C) 2009 PR Newswire. All rights reserved

CTIC, CEPH,

CA-CTIC-Wins-Federal, BUSINESS, csta+stories, financenews, financenews+select, HEALTHCARE, hedge+funds,
prn, PUBCO+SELECT, PUBLIC+COMPANIES, WALL+STREET,

kelvin234

股价不上反而下哦...

葉芬

24/11/09


Cell Therapeutics, Inc. (CTIC) - Still watching CTIC, the stock has been very strong over the past week. I will be buying on a break above $1.21. If this occurs, the volume should really pick up.

m.i.k.e

http://finance.yahoo.com/news/Ne ... 0.html?x=0&.v=1

New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents

葉芬

原帖由 m.i.k.e 于 30-11-2009 03:46 PM 发表
http://finance.yahoo.com/news/New-Class-of-PlatinumBased-prnews-1781308700.html?x=0&.v=1

New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Abi ...

有消息，不過股價沒有動靜。。

葉芬

4/12/09


Cell Therapeutics, Inc. (CTIC) - I am watching CTIC closely....the stock is breaking out. I close above $1.21 would be very bullish.

m.i.k.e

http://finance.yahoo.com/news/Pixantrone-Produces-250-prnews-3456496926.html?x=0&.v=1

Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
Pixantrone increases median overall survival by 48% (or 3.3 month) over standard chemotherapy in patients with relapsed/refractory, aggressive non-Hodgkin's lymphoma who fail two or more prior therapies


NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies. Updated analyses with additional follow-up data were conducted; these analyses and additional follow-up data support the initial clinical trial results. Subgroup analyses examining the effect of age, IPI score, disease status, or prior anthracycline doses on Progression Free Survival (PFS) demonstrated that pixantrone consistently improved PFS across subgroups compared with other chemotherapy agents. With patients in follow-up period at least 9 months from end of treatment, pixantrone provided a 250% relative improvement in 1 year PFS (21% Vs 6%) over comparator and a 115% increase in median overall PFS (5.6 months Vs 2.6 months, p=0.002, HR =0.56). The benefit on PFS was independent of risk factors. At 21 months, 14% of pixantrone patients remained free from disease progression versus 3% in the comparator arm.

"The results of the PIX301 trial continue to impress me as we gain additional follow-up data and information from exploratory sensitivity analyses," noted Dr. Ruth Pettengell, the principal investigator on the study. "The robustness of the drug's effect on prolonging progression free survival across all important risk factors lends to the strength and credibility of the clinical benefit provided to patients in the trial."

The PIX 301 EXTEND (Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive Nhl Disease) trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

Results of the PIX301 phase III trial presented demonstrated improvement across primary and secondary endpoints of the study at a minimum of nine-month follow-up from end of treatment. Pixantrone produced CR / CRu rate of 25.7% versus 7.1% for the comparator arm, p-value = 0.005. Overall response rate also increased significantly in patients that received pixantrone (40.0% pixantrone arm versus 14.3%, p-value=0.001).

Median PFS increased 115% to 5.6 months for pixantrone arm compared to 2.6 for comparator arm, p-value = 0.002 and HR=0.56. Additionally, a positive trend was seen in overall survival with a 48% increase in median overall survival for the pixantrone arm (10.2 months) versus the comparator arm (6.9 months).

Results presented also included a patient subgroup analysis demonstrating that complete response (CR), partial response (PR) and PFS were robust irrespective of risk factors or prior therapy. Pixantrone also provided superior disease control rates over comparator arm with 22 of comparator recipients progressing within the first evaluation point versus 14 for pixantrone recipients.

Despite 50% of patients exceeding cumulative lifetime anthracycline limits (501 - 900 mg/m2), only two cases of congestive heart failure on independent cardiologist assessment were attributed to pixantrone, occurring at lowest drug exposure (<501mg/m2). The follow-up period for the study is ongoing.

"We are pleased that the PIX 301 EXTEND trial of pixantrone not only met its study objective but continues to demonstrate clinical benefit in the follow up period across patient demographics, and risk factors," said James A. Bianco, M.D., Chief Executive Officer of CTI. "We continue to work expeditiously with the FDA as we progress pixantrone through regulatory review to potential approval and commercialization."

The most common (incidence greater than or equal to 10%) grade 3-4 adverse events reported for pixantrone-treated subjects across the studies were neutropenia and leucopenia. Other common adverse events (any grade) included infection, anemia, leucopenia, thrombocytopenia, asthenia, pyrexia, and cough. Although the grade 3/4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (6/68 or 8.8% vs. 3/67 or 4.5%).

The ASH poster is available at http://www.celltherapeutics.com/investor_updates.

Pixantrone is a fast track designated product which has been accepted for review by the U.S. Food & Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.

m.i.k.e

CTIC   1.18
+0.04 (3.51%)

Pre-market: 1.30 +0.12 (10.17%)  <<<<<<加油! (miku 最爱用这招..... )
Dec 7, 4:21AM EST

m.i.k.e

http://www.nasdaq.com/newscontent/20091207/ACQRTT200912070400RTTRADERUSEQUITY_0183.htm

Cell Therapeutics Says Pixantrone Increased Overall Survival By 48% Vs. Standard Chemotherapy In Non-Hodgkin's Lymphoma Patients - Update


(RTTNews) - Biopharmaceutical company Cell Therapeutics, Inc. (CTIC) announced Monday its updated results from the pivotal phase III clinical trial of pixantrone for patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma, who have failed two or more prior therapies. The results demonstrated that pixantrone consistently improved progression free survival across subgroups compared with other chemotherapy agents. Pixantrone increased median overall survival by 48% or 3.3 month over standard chemotherapy.
The updated results of the trial named EXTEND, or PIX 301, were presented in the annual meeting of the University of London during a session at the 2009 American Society of Hematology.
The PIX 301 EXTEND trial was a phase III single-agent trial of pixantrone, enrolling 140 patients, randomized to receive either pixantrone or another single-agent drug currently used for the treatment of the patient population and selected by the physician.
Trial results demonstrated improvement across primary and secondary endpoints of the study at a minimum of nine-month follow-up from end of treatment. Updated analyses with additional follow-up data supported the initial clinical trial results.
Non-Hodgkin lymphoma starts in cells called lymphocytes, a type of white blood cell which are part of the body's immune system. Some non-Hodgkin lymphoma are indolent, while others are very aggressive cancers. In 2009, the estimated new cases and deaths from non-Hodgkin lymphoma in the United States are 65,980 and 19,500, respectively.
Pixantrone is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. It is a fast track designated product which has been accepted for review by the U.S. Food & Drug Administration with action date on April 23, 2010. In September, the group applied for orphan drug designation to the European Medicines Agency or EMEA.
Results presented showed that pixantrone provided superior disease control rates over comparator arm with 22 of comparator recipients progressing within the first evaluation point versus 14 for pixantrone recipients. Complete response, partial response and progression free survival, or PFS, were robust irrespective of risk factors or prior therapy. The benefit on PFS was independent of risk factors.
Cell Therapeutics noted that subgroup analyses examining the effect of age, IPI score, disease status, or prior anthracycline doses on PFS showed that pixantrone consistently improved PFS across subgroups compared with other chemotherapy agents. In the nine-month follow-up period from end of treatment, pixantrone provided a 250% relative improvement in 1 year PFS over comparator and a 115% increase in median overall PFS. At 21 months, 14% of pixantrone patients remained free from disease progression versus 3% in the comparator arm.
"We are pleased that the PIX 301 EXTEND trial of pixantrone not only met its study objective but continues to demonstrate clinical benefit in the follow up period across patient demographics, and risk factors. We continue to work expeditiously with the FDA as we progress pixantrone through regulatory review to potential approval and commercialization," commented James Bianco, M.D., Chief Executive Officer of Cell Therapeutics.
CTIC finished Friday's trading at $1.18, on the Nasdaq. In the after hours, it picked up $0.04 or 3.39%.
For comments and feedback: contact editorial@rttnews.com

jochen

闭关好久。。。。

好久好久 没碰。。。。。。错过了 CTIC＆　SNSS....

0.30 想买。。。。来不及。。。。
CTIC.....知道 他有 conference....可是  睡着了。。。。错过。。。。。

roberto

12/8/09

Cell Therapeutics, Inc. (CTIC)- CTIC looks like it will close above $1.21 Monday, very bullish. Iwould be a buyer of any 10-15% correction as the stock is starting anew uptrend. Resistance is now located at $1.30.

jochen

怎么卡贴。。。卡的那么严重！！！

roberto

12/9/09 December 9, 2009
Cell Therapeutics, Inc. (CTIC)- Tuesday's low was $1.21 so CTIC is holding previous resistance whichis now solid support. Keep an eye on $1.28 & $1.31, a break abovethose two levels should start a new break out.

葉芬

10/12/09

Cell Therapeutics, Inc. (CTIC) - Looking to buy CTIC again when it breaks above $1.31. I also like pullbacks to $1.10.

葉芬

16/12/09


Cell Therapeutics, Inc. (CTIC) - CTIC is hanging out at support which is located around $1.08. I will be a buyer for a trade when the stock clears $1.30 on the upside.

软趴趴

hai ka.....

软趴趴

po kaa.......

软趴趴

zai po ka...........

软趴趴

crazy  po ka ka.............